ArticleHeliyon2024
Seroprevalence of antibodies against diphtheria, tetanus, and pertussis across various age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Seroprotection to five vaccine-preventable diseases among children in East New Britain, Papua New Guinea.The Lancet regional health. Western Pacific · 2026Article
- Pertussis epidemiology and seroprevalence in Wujin District, Changzhou, China, 2024.BMC infectious diseases · 2026Article
- Investigation and analysis of pertussis antibody levels among healthy people in Hangzhou, Zhejiang Province from 2021 to 2024.Frontiers in public health · 2026Article
- Natural immune boosting biases pertussis infection estimates in seroprevalence studies.Nature communications · 2025Article
- Global burden of diphtheria, 1990-2021: a 204-country analysis of socioeconomic inequality based on SDI and DTP3 vaccination differences before and after the COVID-19 pandemic (GBD 2021).Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited data exists regarding population immunity against diphtheria, tetanus, and pertussis in Thailand during the post-COVID-19 pandemic period. This study aimed to evaluate the age-specific seroprevalence of anti-diphtheria toxoid (anti-DT) IgG, anti-tetanus toxoid (anti-TT) IgG, and anti-pertussis toxin (anti-PT) IgG in individuals across diverse age groups in Chonburi province, Thailand following the COVID-19 pandemic. Methods: Between October 2022 and January 2023, a total of 657 participants from Chonburi Province, Thailand, were included in this study. The participants were categorized into 9 age groups: <5, 5-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, and >70 years. Analysis of anti-DT, anti-TT, and anti-PT IgG levels was conducted using commercial ELISA kits (EUROIMMUN, Lübeck, Germany). Results: Overall, 65.4 % of the population had seroprotection against diphtheria (antibody level ≥0.1 IU/mL), while 95.1 % had seroprotection against tetanus (antibody level ≥0.1 IU/mL). The 31-40 years age group exhibited the lowest seroprotection for diphtheria (48.9 %), and the >70 years age group had the lowest seroprotection for tetanus (73.3 %). The <5 years age group showed the highest seropositive rate and highest geometric mean titers for anti-PT IgG. On the contrary, the majority of individuals over 11 years of age displayed anti-PT IgG levels below 40 IU/mL. Conclusions: To prevent diphtheria and pertussis outbreaks in Chonburi province, implementing catch-up vaccination is necessary. Targeted interventions should be deployed to enhance vaccination coverage among the susceptible population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.